LILRB1 and Miyoshi myopathy: NSG mice bearing LILRB1-KD MM cells displayed significantly slower tumor growth (Fig. 2a–d), lower tumor burden (Fig. 2e, f), impaired tumor infiltration into BM (Fig. 2g, h), and better survival (Fig. 2i, j) compared to CTR-KD MM-bearing mice.